Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O43791

UPID:
SPOP_HUMAN

ALTERNATIVE NAMES:
HIB homolog 1; Roadkill homolog 1

ALTERNATIVE UPACC:
O43791; B2R6S3; D3DTW7; Q53HJ1

BACKGROUND:
The Speckle-type POZ protein, with alternative names HIB homolog 1 and Roadkill homolog 1, is integral to the ubiquitination process, facilitating the degradation of specific target proteins via the cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex. It plays a pivotal role in the regulation of protein stability, including that of BRD2, BRD3, and BRD4, by influencing their ubiquitination and subsequent proteasomal degradation.

THERAPEUTIC SIGNIFICANCE:
Linked to the development of Nabais Sa-de Vries syndrome 1 and 2, the Speckle-type POZ protein's function underscores its potential as a target for therapeutic intervention. Exploring its mechanisms further could lead to breakthroughs in treating these complex developmental disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.